Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer.

Clemens B TempferUrs Giger-PabstZiad HilalAskin DoganGünther A Rezniczek

Published in: Archives of gynecology and obstetrics (2018)

Available evidence from controlled trials (phase I and phase II) and retrospective cohort studies in > 1500 patients unequivocally demonstrates that PIPAC is feasible, safe, and effective. PIPAC maintains quality of life in patients with recurrent cancer and PC. PIPAC is as evidence-based as any other treatment in women with ovarian cancer and PC beyond the third line of systemic chemotherapy and can be recommended in this indication.

Keyphrases

systematic review
phase ii
clinical trial
end stage renal disease
newly diagnosed
ejection fraction
open label
peritoneal dialysis
locally advanced
meta analyses
cross sectional
randomized controlled trial
radiation therapy
patient reported outcomes
study protocol
smoking cessation
double blind
chemotherapy induced